Transcriptome Analysis of Human Glioblastoma Cells Susceptible to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
cancer immunotherapy
glioblastoma multiforme
measles virus
oncolytic viruses
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
02 11 2022
02 11 2022
Historique:
received:
29
08
2022
revised:
20
10
2022
accepted:
28
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) accounts for almost half of all primary malignant brain tumors in adults and has a poor prognosis. Here we demonstrated the oncolytic potential of the L-16 vaccine strain of measles virus (MV) against primary human GBM cells and characterized the genetic patterns that determine the sensitivity of primary human GBM cells to oncolytic therapy. MV replicated in all GBM cells, and seven out of eight cell lines underwent complete or partial oncolysis. RNA-Seq analysis identified about 1200 differentially expressed genes (FDR < 0.05) with at least two-fold expression level change between MV-infected and uninfected cells. Among them, the most significant upregulation was observed for interferon response, apoptosis and cytokine signaling. One out of eight GBM cell lines was defective in type I interferon production and, thus, in the post-interferon response, other cells lacked expression of different cellular defense factors. Thus, none of the cell lines displayed induction of the total gene set necessary for effective inhibition of MV replication. In the resistant cells, we detected aberrant expression of metalloproteinase genes, particularly
Identifiants
pubmed: 36366531
pii: v14112433
doi: 10.3390/v14112433
pmc: PMC9696624
pii:
doi:
Substances chimiques
Interferons
9008-11-1
Vaccines
0
Measles Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Mol Ther Oncolytics. 2022 Jun 06;26:105-119
pubmed: 35795092
Cytokine Growth Factor Rev. 2020 Dec;56:28-38
pubmed: 32660751
Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8
pubmed: 18925850
Mol Ther Oncolytics. 2019 Oct 23;15:186-200
pubmed: 31788553
Curr Opin Virol. 2020 Apr;41:85-97
pubmed: 32861945
Neuro Oncol. 2010 Oct;12(10):1034-42
pubmed: 20494960
mBio. 2019 May 14;10(3):
pubmed: 31088929
Gene Ther. 2013 Apr;20(4):444-9
pubmed: 22914495
J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132
pubmed: 29788332
Curr Gene Ther. 2017;16(6):419-428
pubmed: 28042780
Viruses. 2021 Jul 02;13(7):
pubmed: 34372501
Curr Cancer Drug Targets. 2018;18(2):177-187
pubmed: 28228086
Cancer Res. 2006 Aug 1;66(15):7694-700
pubmed: 16885371
Cell Rep. 2021 Sep 7;36(10):109673
pubmed: 34496248
Tr Inst Im Pastera. 1992;67:86-95
pubmed: 8539772
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Oncotarget. 2015 Dec 29;6(42):44892-904
pubmed: 26539644
Virus Res. 2019 Apr 2;263:145-150
pubmed: 30684519
Nat Immunol. 2019 Sep;20(9):1100-1109
pubmed: 31358997
Semin Cancer Biol. 2007 Jun;17(3):214-8
pubmed: 16750389
Blood Adv. 2018 Dec 11;2(23):3492-3505
pubmed: 30530776
J Thorac Oncol. 2014 Aug;9(8):1101-10
pubmed: 25157763
Cancer Res. 2004 Jul 15;64(14):4919-26
pubmed: 15256464
Cancer Metastasis Rev. 2006 Mar;25(1):9-34
pubmed: 16680569
ACS Omega. 2021 Sep 14;6(38):24535-24544
pubmed: 34604635
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Thorac Oncol. 2020 May;15(5):827-842
pubmed: 31945495
Viruses. 2020 Feb 04;12(2):
pubmed: 32033013
Int J Mol Sci. 2018 Jun 14;19(6):
pubmed: 29899215
Cancer Res. 2012 Apr 1;72(7):1651-60
pubmed: 22315352
Pharmaceuticals (Basel). 2013 Nov 25;6(12):1475-506
pubmed: 24287492
Cancer Lett. 2012 Mar 28;316(2):139-50
pubmed: 22075379
Front Oncol. 2019 Sep 26;9:963
pubmed: 31616641
Nat Rev Cancer. 2014 Aug;14(8):559-67
pubmed: 24990523
Anticancer Res. 2009 May;29(5):1475-82
pubmed: 19443353
Lancet Oncol. 2002 Jan;3(1):17-26
pubmed: 11905600
Viruses. 2016 Nov 16;8(11):
pubmed: 27854326
Front Cell Infect Microbiol. 2013 Jan 08;2:168
pubmed: 23316484
Cancer Res. 2010 Oct 1;70(19):7620-9
pubmed: 20858718
Mol Biol (Mosk). 2018 Jul-Aug;52(4):659-666
pubmed: 30113031
Mol Ther. 2020 Apr 8;28(4):1043-1055
pubmed: 32087150
Mol Ther Oncolytics. 2018 Dec 31;12:147-161
pubmed: 30775418
J Virol Methods. 2013 Jan;187(1):57-64
pubmed: 23018058
Virology. 2014 Feb;450-451:55-63
pubmed: 24503067